Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: Results from the I-SPY 1 TRIAL - CALGB 150007/150012, ACRIN 6657

Journal of Clinical Oncology

Volumn 30, Issue 26, 2012, Pages 3242-3249

  Esserman, Laura J ^a   Berry, Donald A ^c   DeMichele, Angela ^d   Carey, Lisa ^e   Davis, Sarah E ^a   Buxton, Meredith ^a   Hudis, Cliff ^f   Gray, Joe W ^i,j   Perou, Charles ^e   Yau, Christina ^a   Livasy, Chad ^e   Krontiras, Helen ^l   Montgomery, Leslie ^h   Tripathy, Debasish ^b   Lehman, Constance ^m   Liu, Minetta C ^k   Olopade, Olufunmilayo I ⁿ   Rugo, Hope S ^a   Carpenter, John T ^l   Dressler, Lynn ^e   Chhieng, David ^o   Singh, Baljit ^g   Mies, Carolyn ^d   Rabban, Joseph ^a   Chen, Yunn Yi ^a   Giri, Dilip ^f   Van't Veer, Laura ^a   Hylton, Nola ^a   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g NEW YORK UNIVERSITY   (United States)

^h ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

ⁱ OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^j LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^k GEORGETOWN UNIVERSITY   (United States)

^l UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^m UNIVERSITY OF WASHINGTON   (United States)

ⁿ UNIVERSITY OF CHICAGO   (United States)

^o YALE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE MARKER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR VOLUME;

BIOLOGICAL MARKERS; BREAST NEOPLASMS; DIAGNOSTIC IMAGING; DISEASE-FREE SURVIVAL; HUMANS; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECURRENCE; TREATMENT OUTCOME;

EID: 84856522259     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.39.2779     Document Type: Article

References (39)

1. Berry DA, Cronin KA, Plevritis SK, et al: Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784-1792, 2005 (Pubitemid 41549890)
2. Hser YI: Self-reported drug use: Results of selected empirical investigations of validity. NIDA Res Monogr 167:320-343, 1997
3. Valero VV, Buzdar AU, Hortobagyi GN: Locally advanced breast cancer. Oncologist 1:8-17, 1996 (Pubitemid 126669366)
4. Esserman LJ, van 't Veer LJ, Perou C, et al: Biology of breast cancers that present as interval cancers and at young age should inform how we approach early detection and prevention. Cancer Res 69, 2009 (suppl 2; abstr 6034)
5. Carey LA, Dees EC, Sawyer L, et al: The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329-2334, 2007 (Pubitemid 46698581)
6. Rouzier R, Perou CM, Symmans WR, et al: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678-5685, 2005 (Pubitemid 41170290)
7. Bear HD, Anderson S, Smith RE, et al: Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24:2019-2027, 2006 (Pubitemid 46622110)
8. Fisher B, Brown A, Mamounas E, et al: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483-2493, 1997 (Pubitemid 27289876)
9. Buchholz TA, Lehman CD, Harris JR, et al: Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: A National Cancer Institute conference. J Clin Oncol 26:791-797, 2008 (Pubitemid 351265334)
10. Symmans WF, Peintinger F, Hatzis C, et al: Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25:4414-4422, 2007 (Pubitemid 350013847)
11. Esserman LJ, Berry DA, Cheang MC, et al: Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: Results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat [epub ahead of print on December 25, 2011]
12. Hudis CA, Barlow WE, Costantino JP, et al: Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system. J Clin Oncol 25:2127-2132, 2007 (Pubitemid 46972801)
13. Hylton NM, Blume J, Bernreuter W, et al: MRI prediction of response to neoadjuvant chemotherapy for women with locally-advanced breast cancer: Results from the ACRIN 6657/I-SPY Trial. Radiology (in press)
14. Allred DC, Harvey JM, Berardo M, et al: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155-168, 1998 (Pubitemid 28144151)
15. Livasy C, Carey L, DiMichelle A, et al: Biomarkers associated with pathologic complete response to neoadjuvant chemotherapy in women with locally advanced breast cancer: Results from the I-SPY TRIAL (CALGB 150007/150012 & ACRIN 6657). Cancer Res 69, 2009 (suppl 2; abstr 5102)
16. Spyratos F, Ferrero-Poüs M, Trassard M, et al: Correlation between MIB-1 and other proliferation markers: Clinical implications of the MIB-1 cutoff value. Cancer 94:2151-2159, 2002 (Pubitemid 34411971)
17. Reference deleted
18. Buxton MB, Esserman LJ: The Challenge of Integrating Information and Improving Care for Breast Cancer: The I SPY Trial Informatics Effort. American Society of Clinical Oncology Educational Book 2005, pp 503-509
19. Simpson EH: The interpretation of interaction in contingency tables. J R Stat Soc Series B (Methodological) 13:238-241, 1951
20. Berry DA, Cirrincione C, Henderson IC, et al: Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295:1658-1667, 2006
21. Hayes DF, Thor AD, Dressler LG, et al: HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357:1496-1506, 2007 (Pubitemid 47572635)
22. Dawood S, Broglio K, Kau SW, et al: Prognostic value of initial clinical disease stage after achieving pathological complete response. Oncologist 13:6-15, 2008 (Pubitemid 351206692)
23. Baselga J, Bradbury I, Eidtmann H, et al: First results of the NeoALTTO Trial (BIG 01-06/EGF 106903): A phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer. Cancer Res 70, 2010 (suppl 2; abstr S3-3)
24. von Minckwitz G, Eidtmann H, Loibl S, et al: Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the Gepar-Quinto trial. Ann Oncol 22:301-306, 2011
25. Gianni L, Pienkowski T, Im Y-H, et al: Neoadjuvant pertuzumab (P) and trastuzumab (H): Antitumor and safety analysis of a randomized phase II study ('NeoSphere'). Cancer Res 70, 2010 (suppl 2; abstr S3-2)
26. Guarneri V, Frassoldati A, Bottini A, et al: Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial). J Clin Oncol 29:46s, 2011 (suppl; abstr 507)
27. Peintinger F, Buzdar AU, Kuerer HM, et al: Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. Ann Oncol 19:2020-2025, 2008
28. Loi S, Buyse M, Sotiriou C, et al: Challenges in breast cancer clinical trial design in the postgenomic era. Curr Opin Oncol 16:536-541, 2004 (Pubitemid 39482971)
29. Newman LA, Mamounas EP: Review of breast cancer clinical trials conducted by the National Surgical Adjuvant Breast Project. Surg Clin North Am 87:279-305, 2007 (Pubitemid 46695902)
30. Grove AS: Efficiency in the health care industries: A view from the outside. JAMA 294:490-492, 2005
31. Gralow JR, Burstein HJ, Wood W, et al: Preoperative therapy in invasive breast cancer: Pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol 26:814-819, 2008 (Pubitemid 351265335)
32. Buzdar AU, Ibrahim NK, Francis D, et al: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23:3676-3685, 2005
33. Piccart-Gebhart MJ, Procter M, Leyland- Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005 (Pubitemid 41464705)
34. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005 (Pubitemid 41464706)
35. Popovici V, Chen W, Gallas BG, et al: Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res 12:R5, 2010
36. Barker AD, Sigman CC, Kelloff GJ, et al: I-SPY 2: An adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 86:97-100, 2009
37. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
38. Caudle AS, Gonzalez-Angulo AM, Hunt KK, et al: Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28:1821-1828, 2010
39. Hatzis C, Pusztai L, Valero V, et al: A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 305:1873-1881 2011